prazosin / Generic mfg. - LARVOL DELTA

Differential Risks of Dementia, Depression, and Injury Among Common α-Blockers, with Tamsulosin as the Reference Drug: A Real-World Cohort Study in Men with Lower Urinary Tract Symptoms. (PubMed, J Clin Med) - "Patients were grouped by α-blocker type-tamsulosin, doxazosin, terazosin, alfuzosin, silodosin, or prazosin-and matched 1:1 using propensity scores to adjust for demographic, clinical, and psychosocial variables. Given its favorable profile, alfuzosin may be the preferred agent in patients at elevated risk of cognitive or psychiatric disorders. These findings highlight the need for individualized α-blocker selection and long-term pharmacovigilance in BPH management."

Journal • Real-world evidence • Alzheimer's Disease • Benign Prostatic Hyperplasia • CNS Disorders • Dementia • Depression • Mental Retardation • Oncology • Psychiatry

Exploration of neural mechanisms underlying antidepressant-like property of Ziziphora clinopodioides Lam. essential oil using mouse forced swimming test: Involvement of the monoaminergic systems. (PubMed, Curr Res Physiol) - "Moreover, naloxone (non-selective antagonist for opioid receptor subtypes, 1 mg/kg), prazosin (α1-adrenergic receptor antagonist, 1 mg/kg), yohimbine (α2-adrenergic receptor antagonist, 1 mg/kg), propranolol (β-adrenergic receptor antagonist, 2 mg/kg), WAY100635 (selective 5-HT1A receptor antagonist, 0.1 mg/kg), ondansetron (5-HT3 receptor antagonist, 1 mg/kg), haloperidol (non-selective dopamine receptor blocker, 0.2 mg/kg), SCH23390 (selective dopamine D1 receptor blocker, 0.05 mg/kg), sulpiride (selective dopamine D2 receptor blocker, 50 mg/kg) and flumazenil (GABAA/BDZ receptor antagonist, 10 mg/kg) were used to ascertain the neural pathways implicated in the antidepressant-like response of EOZC. However, this effect remained unaffected by naloxone, propranolol and flumazenil. These findings indicate that EOZC elicits antidepressant-like response, which relies on its interaction with noradrenergic, serotonergic and..."

Journal • Preclinical • Addiction (Opioid and Alcohol) • DRD2

Cannabidiol Interactions with Cell Membranes: Implications for Cellular Kinetics of Small Molecules (AES 2025) - "The membranal and lysosomal markers CellMask and LysoTracker, respectively, fluorescein, and the d-glucose analog 2-[N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl) amino]-2-deoxy-D-glucose (2-NBDG) served as model molecules. Transcellular transfer was evaluated in transwell systems (MDCK-MDR1 and BeWo clone b30 cell monolayers) with fluorescein and boron-dipyrromethene (BODIPY) prazosin, respectively... At therapeutic concentrations, CBD can alter membrane properties and affect small-molecule uptake across them. The magnitudes of change observed in our study may underestimate the effects of CBD in vivo, because it does not capture the slow sequestration of CBD in tissues. A better understanding of CBD's effects on membrane permeability can provide novel insights into its mechanisms of action."

Late-breaking abstract • CNS Disorders • Epilepsy • Neuroblastoma • Solid Tumor • ABCB1

An Efficient Neural Network of Cooperating Serotonergic and Noradrenergic Neurons in Modulating SUDEP (AES 2025) - "Clinical Translation PotentialWith its unique integration of circuit neuroscience and translational pharmacology, this work promises to redefine clinical approaches to SUDEP prevention. Using the SUDEP-prone DBA/1 mouse model, we employed integrated approaches: pharmacological interventions (5-hydroxytryptophan, atomoxetine, venlafaxine), in vivo calcium imaging, and optogenetics. Targeted microinjections of receptor antagonists (ketanserin: 5-HT2A; prazosin: NE α-1) into the pre-Bötzinger complex (PBC) assessed local receptor contributions. We demonstrate, for the first time, a robust synergistic interaction between 5-HT and NE in mitigating S-IRA and preventing SUDEP... This study establishes the DR-LC-PBC pathway as a critical network for the synergistic protective action of 5-HT and NE against S-IRA and SUDEP. We identify 5-HT2A and NE α-1 receptors within the PBC as key therapeutic targets. These findings provide a mechanistic foundation for developing novel..."

Late-breaking abstract • CNS Disorders • Epilepsy

Biochemically 'active' pheochromocytoma can be clinically 'silent'. (PubMed, Endocrinol Diabetes Metab Case Rep) - "Pre-operatively, she received alpha-adrenergic receptor blockade (prazosin) followed by beta-adrenergic receptor blockade before undergoing right laparoscopic adrenalectomy...Secondary diabetes mellitus can be seen in up to 50% of cases of pheochromocytomas and paraganglioma, which generally resolves after successful biochemical remission. Adequate α-blockade is preferable to prevent intra-operative haemodynamic instabilities in normotensive pheochromocytomas."

Journal • Cardiovascular • Diabetes • Hypertension • Metabolic Disorders • Oncology • Pain • Solid Tumor

A Study to Learn How Different Forms of the Study Medicine Called Prazosin Are Taken up Into the Blood in Healthy Adults (clinicaltrials.gov) - P1 | N=72 | Not yet recruiting | Sponsor: Pfizer

New P1 trial • Congestive Heart Failure

Examining how norepinephrine hurts behavioral function after spinal cord injury: Evidence of a local effect at the site of injury. (Neuroscience 2025) - "Cellular assays are being conducted to assess hemorrhage, inflammation, and signals related to cell death. We are also examining whether local infusion of an alpha-1 adrenergic antagonist (prazosin) blocks the adverse effect of systemic NE."

CNS Disorders

Chronic prazosin reduces headache symptoms through glymphatic flow enhancement (Neuroscience 2025) - "Instead, the β-antagonist propranolol does not treat the same symptoms. Overall, the pharmacological action of prazosin offers the chance to treat these disabling conditions."

CNS Disorders • Migraine • Pain • Vascular Neurology

High throughput assessment of barrier function using human ipsc-derived brain microvascular endothelial cells (Neuroscience 2025) - "bupropion, mannitol, prazosin, VEGF, and verapamil. CONCLUSIONS Characterization of and testing with the individual cellular components that make up the BBB provides added insight to the functional aspects of this complex system. Human iPSC-derived BMEC offer a robust and reliable source of cells to interrogate the multiple properties of this specialized cell type."

CNS Disorders

E3 ligase CHIP restoration facilitates the effect of α1-adrenoceptor blockage on alleviating lipopolysaccharide-caused cardiac fibrosis via downregulating TGF-BR1 expression and Smad2/3 activation. (PubMed, Mol Biomed) - "Furthermore, we innovatively revealed that α1A-AR is the dominant α1-AR subtype in CFs, and its specific antagonist, silodosin, eliminated NE-mediated CFs differentiation and LPS-induced myocardial fibrosis, which was consistent with the action of prazosin. These findings demonstrate the protective effect of α1-AR blockage against LPS-mediated myocardial fibrosis, which is achieved by directly inhibiting the PKC-p38-Smad2/3 signaling pathway and promoting TGF-BR1 downregulation through restoring CHIP expression."

Journal • Fibrosis • Immunology • Infectious Disease • Septic Shock • Targeted Protein Degradation • JUN • SMAD2 • ST13 • TGFB1

Central injection of epidermal growth factor (EGF) induces hypophagia via D₁ dopaminergic and β₂ adrenergic receptors in broiler chickens. (PubMed, Poult Sci) - "Experiments 2-10 evaluated the effects of co-injection of EGF (200 ng) with various pharmacological agents and receptor antagonists: SCH23390 (D₁-dopaminergic), AMI-193 (D₂-dopaminergic), l-DOPA (dopamine precursor), 6-OHDA (dopaminergic neurotoxin), prazosin (α₁-adrenergic), yohimbine (α₂-adrenergic), metoprolol (β₁-adrenergic), ICI 118,551 (β₂-adrenergic), and SR 59230R (β₃-adrenergic). Antagonists for α₁, α₂, β₁, and β₃ adrenergic receptors, as well as D₂ dopaminergic receptors, had no significant effect on EGF-induced anorexia (P ≥ 0.05). These findings demonstrate, for the first time, that central EGF acts as an appetite-suppressing peptide in broilers, and its effect is specifically mediated through interactions with D₁ dopaminergic and β₂ adrenergic receptor systems."

Journal • Anorexia

The Discovery of α-Adrenoceptor Antagonists as a Potential New Treatment Option for Uveal Melanoma. (PubMed, Biomolecules) - "Drug screening with UM spheroids revealed that prazosin and doxazosin dose-dependently reduced viability, whereas terazosin, alfuzosin, silodosin, tamsulosin, and phenoxybenzamine were found to be inefficient. This suggests a tumor-preventive effect through the blockade of α1A-AR. The present study highlights the responses of UM spheroids to α-AR antagonists and demonstrates that prazosin, doxazosin, or RS17053 may be a treatment option for preventing UM tumor recurrence or metastasis."

Journal • Eye Cancer • Hepatocellular Cancer • Melanoma • Ocular Melanoma • Oncology • Solid Tumor • Uveal Melanoma • AR

In-vitro Assessment of BCRP-Mediated Efflux of Antiseizure Medications in Human Blood-Brain Barrier Cell Model. (PubMed, J Biochem Mol Toxicol) - "They also influenced the BCRP-mediated BODIPY-prazosin efflux in competitive substrate efflux assay, since N-desmethyl clobazam (1 µM & 10 µM) and oxcarbazepine (12 µM & 140 µM) increased the BODIPY-prazosin intracellular accumulation (p < 0.01). Co-incubation with the BCRP inhibitor significantly reduced the efflux ratios for these two ASMs (p < 0.01), confirming active BCRP-mediated efflux of N-desmethyl clobazam and oxcarbazepine. Collectively, these findings provide evidence that among eight ASMs, N-desmethyl clobazam, and oxcarbazepine may be transported by BCRP at clinically relevant concentrations, and targeting BCRP may potentially enhance future epilepsy treatments."

Journal • Preclinical • Breast Cancer • CNS Disorders • Epilepsy • Oncology • Solid Tumor

Receptor-Specific Noradrenergic Modulation of Oscillatory Dynamics during Non-Rapid Eye Movement sleep in adult male rats. (PubMed, Neuropharmacology) - "To examine receptor-specific effects, we injected intraperitoneally prazosin (α1-AR antagonist, 0.5 mg/kg), propranolol (β-AR antagonist, 10 mg/kg), or clonidine (α2-AR agonist, 0.05 mg/kg). Our findings revealed the state- and receptor-specific noradrenergic modulation of the oscillatory dynamics within the TCH network during NREM sleep. These alterations may have functional implications for sleep quality, homeostatic regulation, and sleep-dependent cognitive processes, and should be considered when using noradrenergic medication."

Journal • Preclinical

Cyclohexylamine, the principal metabolite of cyclamate, contracts the epididymal vas deferens of rats by affecting endogenous catecholamine release via postsynaptic α1A- and presynaptic α2-adrenoceptors in a calcium-dependent manner. (PubMed, Biomedicine (Taipei)) - "Calcium-channel blocker, nifedipine (1 × 10-8M-1 × 10-6 M) or verapamil (1 × 10-8M-1 × 10-5 M) pretreatment, dose-dependently attenuated the CHA (1 × 10-4 M)-induced contraction...Prazosin (1 × 10-8M-1 × 10-6 M) or yohimbine (1 × 10-7 M-1 × 10-5 M) pretreatment or treatment could inhibit contractions evoked by CHA (1 × 10-4 M) in a dose-dependent manner...Moreover, reserpine (1 × 10-5 M) showed a significant inhibition on the contractions of CHA (1 × 10-4 M). From the above results, CHA-contracts epididymal vas deferens of rats by affecting endogenous catecholamine release via postsynaptic α1A- and presynaptic α2- adrenoceptors and are calcium-dependent."

Journal • Preclinical • Oncology

NORADRENERGIC AND NITRIC OXIDE MODULATORS INFLUENCE ANTIDEPRESSANT EFFECTS OF AGOMELATINE IN MICE (WCN 2025) - "Agomelatine (40 mg/kg), imipramine (10 mg/kg, a tricyclic antidepressant), bupropion (10 mg/kg, dopamine /norepinephrine-reuptake inhibitor), prazosin (1 mg/kg, an α1-adrenoceptor antagonist), yohimbine (1 mg/kg, an α2-adrenoceptor antagonist), and propranolol (2 mg/kg, a β-adrenoceptor antagonist), L-arginine (100 mg/kg, NO precursor), L-NAME (10 mg/kg, NO synthetase inhibitor), methylene blue (5mg/kg, guanylate cyclase inhibitor) were injected 30 min before administration of agomelatine, α-methyl-p-tyrosine (100 mg/kg, an inhibitor of tyrosine hydroxylase) was administered 3 h before agomelatine. Agomelatine proved potential antidepressant effects, that was enhanced by adrenergic or nitric oxide pathway modulation. Further research is warranted to determine the precise molecular mechanisms and optimize clinical applications."

Preclinical • CNS Disorders • Depression • Psychiatry

Treatment-resistant ocd in an adult patient with autism spectrum disorder and nbea gene deletion: a case report (ECNP 2025) - "Despite treatment with multiple SSRIs (duloxetine, sertraline, paroxetine), TCA (clomipramine) and low doses of antipsychotics (risperidone, brexpiprazole), her symptoms persisted...Notably, a case in the literature described a patient with ASD and an NBEA deletion who exhibited paranoid behaviors and responded positively to prazosin, an alpha-1 adrenergic antagonist...Early genetic screening may help identify individuals at risk for ASD, OCD, and associated behavioral disturbances, allowing for more tailored interventions. Further research is needed to clarify the neurobiological mechanisms underlying NBEA-associated phenotypes and to develop more effective therapeutic approaches."

Case report • Clinical • CNS Disorders • Mental Retardation • Mood Disorders • Obsessive-Compulsive Disorder • Psychiatry • NBEA

REAL-WORLD IMPLICATIONS OF THE NEW AASLD/IDSA HCV "TEST AND TREAT" ALGORITHM: FOCUS ON CARDIOVASCULAR COMEDICATIONS IN HEPATITIS C VIRUS (HCV) PATIENTS RECEIVING DIRECT-ACTING ANTIVIRALS (DAAS) (AASLD 2025) - " We leveraged the IQVIA PharMetrics Plus claims database (July 2015-June 2023) to evaluate the co-administration of statins and antihypertensive drugs with pDAAs, specifically sofosbuvir/velpatasvir (SOF/VEL) or glecaprevir/pibrentasvir (GLE/PIB), in US patients...All 321 contraindications among statin users were associated with GLE/PIB, specifically involving atorvastatin, lovastatin, and simvastatin. For antihypertensives, olmesartan, prazosin, and enalapril were the most common comedications posing a clinically significant DDI risk. Applying the new AASLD/IDSA algorithm, especially when statins or antihypertensives are co-administered with pDAAs, would necessitate specialist consultation for a significant number of patients due to DDI risk. This potential barrier to rapid "test and treat" implementation could be substantially reduced by carefully selecting the DAA regimen based on individual patient DDI risk profiles."

Clinical • Real-world • Real-world evidence • Cardiovascular • Hepatitis C • Hepatology • Infectious Disease • Inflammation

Drug Repurposing for Targeting Cancer Stem-like Cells in Glioblastoma. (PubMed, Cancers (Basel)) - "These mainly included antidiabetics (e.g., Metformin, Phenformin, and Sitagliptin), antihypertensives (e.g., Nicardipine, Doxazosin, and Prazosin), antimicrobials (e.g., Pyrvinium pamoate, Flubendazole, and Clofazimine), and central nervous system-acting drugs (e.g., Chlorpromazine, Fluvoxamine, and Disulfiram)...Also significant were those drugs tested in combination, resulting in increased sensitivity to Temozolomide (TMZ), the standard pharmacological treatment available for GBM...Importantly, major translational barriers remain, like limited blood-brain barrier penetration and the lack of robust clinical trials. In conclusion, drug repurposing is an affordable and suitable strategy to target GSCs, impairing cell viability, reducing stemness, and enhancing their sensitivity to TMZ, which has potential that should be further explored to improve patients' clinical outcomes."

Journal • Review • Brain Cancer • Glioblastoma • Glioma • Oncology • Solid Tumor

Generalised bullous pemphigoid in a young man after exposure to haemodialysis membrane: a case report (EADV 2025) - "Hemodialysis was temporarily discontinued, and the patient was started on injectable furosemide, oral nifedipine, and prazosin for management of his ESRD-related complications...Due to the severity of his symptoms, HD was again discontinued, and the dose of oral prednisolone was increased to 1.5 mg/kg/day... This case illustrates an atypical presentation of bullous pemphigoid in a young male with ESRD, triggered following exposure to a polysulfone membrane during hemodialysis. Prior studies have suggested that BP in HD patients may be triggered by materials used in the dialysis process. In our case, the polysulfone membrane may have played a significant role by activating eosinophils in the bloodstream and skin, subsequently promoting the formation of autoantibodies against the BP180 and BP230 antigens."

Case report • Clinical • Bullous Pemphigoid • Chronic Kidney Disease • Dermatology • Dermatopathology • Immunology • Infectious Disease • Nephrology • Pruritus

POST-TRAUMATIC HEADACHE: CLINICAL IMPACT AND NEW THERAPEUTIC STRATEGIES (IHC 2025) - "Some studies, however, had methodological limitations that prevented definitive conclusions on the use of amitriptyline and prazosin. Conclusion Post-traumatic headache is a multifactorial condition, marked by alterations in neuropeptide pathways (CGRP and PACAP-38) and neurovascular hypersensitivity mediated by ion channels (K_ATP and BKCa). Therapeutic strategies such as rTMS, the use of erenumab, botulinum toxin type A and behavioral interventions, associated with changes in lifestyle and sleep hygiene, have shown significant benefits, highlighting the need for further research to consolidate these approaches in the management of PTSD."

Clinical • CNS Disorders • Migraine • ADCYAP1

Chronic prazosin reduces headache symptoms through glymphatic flow enhancement (IHC 2025) - "Propranolol, a beta noradrenergic receptor antagonist, did not rescue CGRP-induced sensitivity in the same mTBI mouse model. Conclusion The pharmacological action of prazosin offers the chance to treat headache and PTH symptoms."

Migraine

Status of Imagery Rehearsal Therapy and Other Interventions for Nightmare Treatment in PTSD. (PubMed, Curr Psychiatry Rep) - "Imagery rehearsal therapy (IRT) and prazosin remain the most supported treatments, though results vary across studies...While trauma-focused treatments reduce PTSD symptoms, nightmares may persist without targeted care. Standardized CBT-based approaches, consistent outcome measurement, and studies on mechanisms and sequencing are needed to optimize and expand access to nightmare treatment."

Journal • Review • CNS Disorders • Insomnia • Mood Disorders • Post-traumatic Stress Disorder • Sleep Disorder

Intentional Ingestion and Multidisciplinary Management in a Fatal Polypharmacy Overdose. (PubMed, Ann Afr Med) - "In the present case study, a 22-year-old male medical student with a known history of depression and recurrent episodes of suicide who was on regular psychiatric medications purposefully consumed an unknown quantity of clonazepam, prazosin, ivabradine, and propranolol in an attempt of suicide in a powdered form. The patient was also put on vasopressin assistance to prevent further damage to vital organs and death. This case report highlights the importance of early detection, vigorous cardiovascular stabilization, prompt intervention, and comprehensive psychological management in preventing recurrence in such cases of fatal polypharmacy cases."

Journal • Cardiovascular • CNS Disorders • Depression • Hypotension • Psychiatry • Respiratory Diseases

Pilot Study Objectively Identifies Veterans with PTSD and Nightmares from Polysomnograms Using a Chaos Theory Approach (WSS 2025) - "1. The sleep pattern is significantly different between a Veteran without PTSD (Panel A) and a Veteran with PTSD (Panel B) and a Veteran with OSA (Panel C).2. The heterogeneity within Veterans with PTSD (Panel G) and OSA (Panel H) could be explained by age & medications.3."

Clinical • Cardiovascular • CNS Disorders • Hypertension • Obstructive Sleep Apnea • Post-traumatic Stress Disorder • Respiratory Diseases • Sleep Disorder • Vascular Neurology